Inside USP: Characterization of Heparin Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Characterization of Heparin Products
USP workshop participants support new methods to safeguard heparin products but desire international harmonization. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 10

Conclusions

Regulatory expectations regarding the quality of UFH have increased since the global heparin crisis of 2008. Industry has witnessed modernization of pharmacopeial methods that demand higher criteria for all quality attributes. Orthogonal tests have been implemented to identify heparin and to demonstrate lack of contaminants. At the workshop, USP and FDA jointly announced their intent to further revise heparin monographs to ensure the continued supply of safe and effectve heparin for patients. USP will update heparin stakeholders about the status of the monograph revisions and will ensure sufficient time for a public evaluation of the procedures, specifications, and implementation date.

Anita Y. Szajek, PhD, is a senior scientific liaison, Tina S. Morris, PhD, is vice-president of biologics & biotechnology, both at the US Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790, tel. 301.816.8325,

References

1. USP Heparin Hot Topics Page, http://www.usp.org/hottopics/heparin.html, accessed Aug. 27, 2009.

2. USP Heparin Workshop Page, http://www.usp.org/meetings/workshops/heparinWorkshop2009.html, accessed Aug. 27, 2009.

3. FDA, Information on Heparin (2009), http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112597, accessed Aug. 27, 2009.

4. M. Guerrini et al., "Oversulfated Chondroitin Sulfate Is a Contaminant in Heparin Associated with Adverse Clinical Events," Nature Biotechnol. 26 (6), 669–675 (2008).

5. EMEA, Guideline on Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparins (London, March 2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here